By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
‘And then we saw the little head.’ Scientists witness rare sperm whale birth - 2Farmers call for French blockades over cow disease cull
- 3From Novice to Master: Dominating a Side interest
- 4Top Breakfast Food: What's Your Morning Enjoyment?
- 5Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
- 'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- Figure out How to Back Your Rooftop Substitution
- Foot fossil discovery could reshape human evolutionary history
- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- 5 Arising Professions in Environmentally friendly power
